Beijing Lepu Medical Technology Co., Ltd. is a wholly-owned subsidiary of Lepu (Beijing) Medical Equipment Co., Ltd. (sz.300003) with a registered capital of 30 million yuan. It is a diversified collective enterprise integrating R&D, diagnostic reagent products and related equipment.
As a wholly-owned subsidiary of Lepu Medical, Lepu Technology's in vitro diagnostic products enrich the product line of the group company, which mainly focuses on equipment and consumables, and help Lepu become the largest and most professional cardiovascular medical industry chain group company in China.
Lepu's products include POCT bedside diagnosis series, CFMS Sifen coagulation detection series and molecular diagnosis series of cardiovascular diseases under research. And successfully established professional technical platforms such as nano-immunity, fluorescence detection, microfluidic, chemiluminescence and monoclonal antibody preparation. The company adopted advanced technology to develop a new generation of POCT immunoquantitative analyzer and its supporting reagents, which were well received by the domestic market and exported to more than ten countries such as Europe, Asia and Latin America. The company is the first enterprise in China to independently research and develop the complete analysis equipment for coagulation and fibrinolysis. CFMS Saffens Thromboelastogram and its matching reagent products can be called national brands of blood coagulation testing, which breaks the monopoly of European and American products and fills the gap in China. Molecular diagnosis technology makes Lepu technology walk in the forefront of high-end market in the field of inspection.
With the joint efforts of the energetic team and relying on the rich resources of the group company in the field of cardiovascular medical care, Lepu Technology will strive to become a first-class cardiovascular disease diagnosis expert in China.